Year: 2024

BioXcel Therapeutics to Present at ThinkEquity Conference

Written by Customer Service on October 29, 2024. Posted in Public Companies.

NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO, and Vincent J. O’Neill, M.D., Executive Vice President, Chief of Product Development and Medical Officer, will present at the ThinkEquity Conference in New York City. The presentation is set for Wednesday, October 30 at 2 p.m. ET. To access a live webcast of the presentation, please visit the Events & Presentations page under the “News/Events” tab in the Investors & Media section of the Company’s website at bioxceltherapeutics.com. A webcast replay will be available for 90 days. About BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

Written by Customer Service on October 29, 2024. Posted in Public Companies.

The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical POMPANO BEACH, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will initiate a nationwide launch of Vendaje AC® with Venture Medical, LLC, the Company’s exclusive sales and marketing partner. The launch is scheduled to commence in the fourth quarter and will cover every Medicare Administrative Contractor (MAC) region across the United States. Jason Matuszewski, CEO of BioStem Technologies Inc., commented: “This is a pivotal moment for BioStem Technologies. With nationwide Medicare...

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Written by Customer Service on October 29, 2024. Posted in Public Companies.

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. Truist Securities BioPharma SymposiumDate: November 7, 2024Location: Lotte New York Palace – New York, NYFormat: 1×1 meetings only UBS Global Healthcare ConferenceDate: November 13, 2024Location: Rancho Palos Verdes, CAFormat: Fireside ChatTime: 2:45 p.m. – 3:20 p.m. PT / 5:45 p.m. – 6:20 p.m. ET Stifel 2024 Healthcare ConferenceDate: November 18, 2024Location: New York, NYFormat: Fireside ChatTime:...

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

Written by Customer Service on October 29, 2024. Posted in Public Companies.

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations from across its broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2024, being held Oct. 29 – Nov. 2, 2024, in Boston, Massachusetts. Details for the presentations are as follows: Major Depressive Disorder Title: AXS-05 (Auvelity®) in Major Depressive Disorder: Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND)Presentation Date and Time: Thursday, Oct. 31, 1:30 – 3 p.m. and Friday, Nov. 1, 1:30 – 3 p.m. ETLead Author: Craig Chepke, MD, SUNY Upstate Medical UniversityPoster Number: 171 Title: Effects of AXS-05...

Creative Realities Inc. Shines as a Top Workplace, Empowering Employees in Greater Louisville

Written by Customer Service on October 29, 2024. Posted in Public Companies.

Digital signage leader earns recognition for its commitment to fostering a motivating and supportive workplace culture LOUISVILLE, Ky., Oct. 29, 2024 (GLOBE NEWSWIRE) — Creative Realities, Inc. (NASDAQ: CREX, CREXW), a leading provider of digital signage and media solutions, is pleased to announce it was named a Top Workplace in the Greater Louisville area. This recognition is based on employee feedback gathered through the Energage Workplace Survey, a research-backed tool that captures valuable insights on workplace engagement and culture, facilitated by the Louisville-Courier. “We’re incredibly honored to be named a Top Workplace,” said Rick Mills, CEO of Creative Realities. “This recognition is a direct reflection of our talented and dedicated team, and validates our core values that we cultivate and demonstrate every day.” The...

Evergold Options the Rockland Gold Property to Wolfden, and Wolfden Prepares to Drill

Written by Customer Service on October 29, 2024. Posted in Mergers And Acquisitions.

TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) — Evergold Corp. (TSX-V: EVER, OTC: EVGUF, WKN: A2PTHZ) (“Evergold” or the “Company”) is pleased to announce that it has granted Wolfden Resources Corporation (“Wolfden”) an option to acquire in two stages up to a 75% interest in the Company’s drill-permitted, past producing Rockland gold-silver property, located south of Yerington in Nevada’s Walker Lane geological belt. It is anticipated that the agreement will lead to the commencement of a minimum 5,000 feet of core drilling in the near future. Under the first stage, Wolfden may earn an initial 51% interest by completing $US1.175 million in exploration expenditures before January 1, 2026, including posting a drilling bond with the U.S. Forest Service by December 15 this year, and making cash payments totaling $US600,000 to the underlying...

Quris-AI Acquires Nortis

Written by Customer Service on October 29, 2024. Posted in Mergers And Acquisitions.

Adds Proven Kidney-on-Chip Technology to Its Pioneering Bio-AI Platform BOSTON and TEL AVIV, Israel, Oct. 29, 2024 (GLOBE NEWSWIRE) — Quris-AI (Quris), a leading Bio-AI company focused on revolutionizing the pharmaceutical drug development process, today announced the successful asset acquisition of Nortis, recently known as Numa Biosciences, Inc., and will be opening access to publicly funded data within its expansive microphysiology systems (MPS) database. Quris-AI will integrate Nortis’s pioneering Kidney-on-Chip technology, already vetted by the National Center for Advancing Translational Sciences (NCATS) under the National Institutes of Health (NIH), with its Bio-AI platform. Nortis’s Kidney-on-Chip models, which set new standards for in-vitro drug testing and personalized medicine, will be combined with Quris-AI’s advanced...

Crane NXT Acquires Smart Packaging Assets of TruTag Technologies, Further Expanding Capabilities in Product Security and Authentication Technologies

Written by Customer Service on October 29, 2024. Posted in Mergers And Acquisitions.

WALTHAM, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) — Crane NXT, Co. (NYSE: CXT) (“Crane NXT” or the “Company”), a premier industrial technology company, today announced that it has completed the acquisition of the Smart Packaging assets of TruTag Technologies. TruTag provides secure digitization of physical products through proprietary secure marking and smartphone authentication. “The addition of this technology to Crane NXT’s product portfolio is an exciting expansion of our capabilities and further enhances our ability to provide differentiated and innovative technology solutions to our customers,” Aaron W. Saak, Crane NXT’s President and Chief Executive Officer, said. “TruTag’s Smart Packaging technology will also expand our capability for direct-to-product marking in both consumer and industrial applications...

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Written by Customer Service on October 29, 2024. Posted in Earnings Releases And Operating Results.

WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, November 12, 2024 to report its third quarter 2024 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. About NeumoraNeumora Therapeutics,...

Scorpio Tankers Inc. Announces Financial Results for the Third Quarter of 2024 and the Declaration of a Dividend

Written by Customer Service on October 29, 2024. Posted in Earnings Releases And Operating Results.

MONACO, Oct. 29, 2024 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE: STNG) (“Scorpio Tankers” or the “Company”) today reported its results for the three and nine months ended September 30, 2024. The Company also announced that its board of directors (the “Board of Directors”) has declared a quarterly cash dividend on its common shares of $0.40 per share. Results for the three months ended September 30, 2024 and 2023 For the three months ended September 30, 2024, the Company had net income of $158.7 million, or $3.31 basic and $3.16 diluted earnings per share. For the three months ended September 30, 2024, the Company had adjusted net income (see Non-IFRS Measures section below) of $87.7 million, or $1.83 basic and $1.75 diluted earnings per share, which excludes from net income (i) a $69.3 million,...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals